Lithium carbonate may have the potential to be a neuroregenerative agent for SCI (Yang et al. 2012).
In a double blind placebo controlled randomized trial, Yang et al. (2012) found that individuals that received lithium carbonate had markedly reduced VAS scores over a 6 week period and at 6 month follow-up compared to the placebo group.
There is level 1b evidence (from one RCT: Yang et al. 2012) that lithium carbonate may reduce neuropathic pain post SCI.